Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy.
In this study, we used intratumor delivery of adenoviral vectors to induce a selective anti-tumor response by combining the potent angiogenesis inhibitor murine angiostatin (adenovirus (Ad)-angiostatin) with the powerful immune simulator and angiostatic cytokine murine IL-12 (Ad-IL-12). In a murine model of breast carcinoma, intratumor injection of Ad-angiostatin delayed mean tumor growth, as compared with control virus with an initial regression of tumor growth, in 65% of treated animals. However, all treated animals eventually succumbed to the tumors. Mice injected with Ad-IL-12 alone responded with an initial regression in 20% of treated animals, with only 13% developing a total regression. Coinjection of the vectors resulted in 96% of the treated animals developing an initial regression, with 54% undergoing a total regression of the tumor. These mice were resistant to tumor rechallenge and developed a strong CTL response. Frozen tumor sections were stained for microvessel density using an Ab against murine CD31, an endothelial cell marker. Automated image analysis revealed the mean microvessel density following the administration of Ad-angiostatin and Ad-IL-12 alone or in combination was significantly reduced compared with the control-treated tumor. In summary, we have shown that a short-term course of antiangiogenic therapy combined with immunotherapy can effectively shrink a solid tumor and vaccinate the animal against rechallenge. The rationale for this therapy is to limit the tumor size by attacking the vasculature with angiostatin, thereby allowing IL-12 to mount a T cell-specific response against the tumor AG:
Gyorffy
S
S
Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
Palmer
K
K
Podor
T J
TJ
Hitt
M
M
Gauldie
J
J
D000230:Adenocarcinoma / Q000098:blood supply / Q000235:genetics / Q000276:immunology / Q000628:therapy; D000260:Adenoviruses, Human / Q000235:genetics*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D043168:Angiostatins; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000096:biosynthesis / Q000235:genetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002461:Cell Line, Transformed; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D007106:Immune Sera / Q000032:analysis; D007150:Immunohistochemistry; D016233:Immunotherapy, Active / Q000379:methods; D015552:Injections, Intralesional; D007279:Injections, Subcutaneous; D018664:Interleukin-12 / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics*; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000737:chemistry / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D010446:Peptide Fragments / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics*; D010958:Plasminogen / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000276:immunology; D013194:Staining and Labeling; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D000952:Antigens, Polyomavirus Transforming; D007106:Immune Sera; D010446:Peptide Fragments; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D018664:Interleukin-12; D043168:Angiostatins; D010958:Plasminogen